Trial Profile

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trotabresib (Primary)
Indications Adenocarcinoma; Astrocytoma; Basal cell cancer; Carcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Glioblastoma; Glioma; Marginal zone B-cell lymphoma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Salivary gland cancer; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Celgene Corporation

07 Oct 2024 Status changed from active, no longer recruiting to discontinued. (Business objectives have changed)
09 Sep 2024 Planned End Date changed from 15 Jun 2026 to 5 Sep 2024.
09 Sep 2024 Planned primary completion date changed from 31 Jul 2024 to 5 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com